Calobrace MB, et al. From bench to bedside: clinical implications of a 4-micron surface. Aesthet Surg J. 2026;46(S2):S96-S108. doi: 10.1093/asj/sjag115
Disclosure
Dr. Epstein is a paid investigator in the Motiva U.S. FDA clinical trial and is compensated by Establishment Labs to train surgeons on the Preservé breast augmentation technique. He discloses this relationship in all public communications involving Motiva or Preservé. Dr. Epstein owns stock in Establishment Labs.
What This Study Found
This review connects laboratory research on a specific, very fine implant surface texture (4 microns) to what surgeons actually see in patients: how the body's own tissue integrates with the implant surface, and how that relates to lower rates of scar tissue tightening around the implant (capsular contracture).
Key Findings
- Reviews the biologic and mechanical rationale for a 4-micron implant surface texture
- Connects laboratory tissue-integration data to clinical outcomes reported elsewhere in the literature
- Important distinction: this is about the implant surface technology itself, separate from the tissue-preservation surgical technique. It should not be conflated with Dr. Epstein's own Preservé surgical outcomes data, which come from a different source entirely
Why This Matters for Preservé Patients
Useful for explaining why implant surface technology matters on its own, as a complement to (not a substitute for) the surgical technique pages elsewhere in this library.
